Biostar Pharmaceuticals, Inc. (BSPM) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Biostar Pharmaceuticals, Inc. (BSPM) trades at $0.0001 with AI Score 47/100 (Grade C). Biostar Pharmaceuticals, Inc. focuses on developing, manufacturing, and marketing pharmaceutical products in China. Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for BSPM: BSPM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BSPM against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BSPM: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Biostar Pharmaceuticals, Inc. (BSPM) Healthcare & Pipeline Overview
Biostar Pharmaceuticals, Inc., based in China, develops and markets OTC and prescription pharmaceutical products, including its key product Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B. The company distributes its products across 28 provinces in China, leveraging both distributors and a direct sales network.
What Is the Investment Thesis for BSPM?
Biostar Pharmaceuticals operates in the Chinese pharmaceutical market, focusing on both OTC and prescription drugs. The company's key product, Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B, addresses a significant health issue in China. However, with a negative profit margin of -239.0% and a market capitalization of $0.00B, the company faces significant financial challenges. Potential growth catalysts include expanding its product line and increasing its market penetration within China. Investors should carefully consider the risks associated with investing in OTC-listed companies, including liquidity and disclosure concerns.
Based on FMP financials and quantitative analysis
BSPM Key Highlights
- Gross Margin of 38.4% indicates potential for profitability if costs are managed effectively.
- Operates in 28 provinces in China, demonstrating a significant distribution network.
- Offers both OTC and prescription drugs, diversifying its revenue streams.
- Key product, Xin Ao Xing Oleanolic Acid capsule, targets chronic hepatitis B, a significant health issue in China.
- Profit Margin of -239.0% signals financial challenges requiring strategic intervention.
Who Are BSPM's Competitors?
BSPM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ELOX Eloxx Pharmaceuticals, Inc. | $11.65 | -2.92% | $88.2M | 34 |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.14 | +0.21% | $40.3M | 61 |
| MNNGF Baijin Life Science Holdings Limited | $0.07 | +0.00% | $58.0M | 63 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| SHIEF Shield Therapeutics plc | $0.08 | +0.00% | $84.8M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BSPM's Key Strengths?
- Established distribution network in China.
- Portfolio of both OTC and prescription drugs.
- Focus on traditional Chinese medicine.
- Online platform for HBV patients.
What Are BSPM's Weaknesses?
- Negative profit margin.
- Limited financial resources.
- Dependence on a single key product (Xin Ao Xing).
- OTC listing indicates higher risk.
What Could Drive BSPM Stock Higher?
- Potential regulatory approvals for new pharmaceutical products.
- Expansion of the company's distribution network in China.
- Increased adoption of the China Hepatitis Internet hospital platform.
What Are the Key Risks for BSPM?
- Financial-distress signal — its Altman Z-Score of 0.02 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-14.0%) — the business is not currently generating profit on shareholder capital.
- Competition from larger pharmaceutical companies.
- Regulatory changes in China.
- Fluctuations in raw material prices.
- Economic slowdown in China.
- Negative profit margin and limited financial resources.
What Are the Growth Opportunities for BSPM?
- Expanding its OTC product line: Biostar can capitalize on the growing demand for OTC medications in China by introducing new products targeting common ailments. The Chinese OTC market is projected to reach $50 billion by 2028, offering significant revenue potential. Timeline: Launching 2-3 new OTC products annually over the next 3-5 years could significantly boost revenue.
- Increasing market penetration in existing provinces: Biostar currently operates in 28 provinces in China. Deepening its market penetration within these regions through targeted marketing and sales initiatives can drive revenue growth. The pharmaceutical market in these provinces is estimated at $200 billion, offering ample opportunity for expansion. Timeline: Achieving a 1% increase in market share in each province over the next 2 years.
- Leveraging its online platform: Biostar's China Hepatitis Internet hospital provides a direct channel to reach HBV patients. Expanding the platform's services and offerings, such as online consultations and prescription refills, can enhance customer engagement and drive sales. The online healthcare market in China is projected to reach $40 billion by 2027. Timeline: Expanding online services and increasing user engagement by 20% annually.
- Developing new prescription drugs: Biostar can invest in research and development to create new prescription drugs targeting unmet medical needs in China. The prescription drug market in China is projected to reach $300 billion by 2028. Timeline: Launching 1-2 new prescription drugs every 3 years.
- Strategic partnerships and acquisitions: Biostar can explore strategic partnerships or acquisitions to expand its product portfolio, market reach, and technological capabilities. The Chinese pharmaceutical market is consolidating, presenting opportunities for strategic alliances. Timeline: Pursuing 1-2 strategic partnerships or acquisitions over the next 5 years.
What Opportunities Does BSPM Have?
- Expanding OTC product line.
- Increasing market penetration in existing provinces.
- Leveraging online platform for growth.
- Developing new prescription drugs.
What Threats Does BSPM Face?
- Competition from larger pharmaceutical companies.
- Regulatory changes in China.
- Fluctuations in raw material prices.
- Economic slowdown in China.
What Are BSPM's Competitive Advantages?
- Established distribution network in 28 provinces in China.
- Focus on traditional Chinese medicine.
- Key product targeting chronic hepatitis B, a significant health issue in China.
- Online platform providing direct access to HBV patients.
What Does BSPM Do?
Biostar Pharmaceuticals, Inc., established in 2007 and headquartered in Xianyang, China, is engaged in the development, manufacture, and marketing of pharmaceutical products. The company's portfolio includes both over-the-counter (OTC) and prescription medications, addressing a variety of diseases and conditions prevalent in the Chinese market. Its primary product is Xin Ao Xing Oleanolic Acid capsule, an OTC medicine indicated for chronic hepatitis B, a significant health concern in China. In addition to Xin Ao Xing, Biostar offers 12 other OTC products and 17 prescription-based pharmaceuticals, catering to a broad spectrum of healthcare needs. Biostar's OTC product line includes Ganwang compound paracetamol and amantadine hydrochloride capsule for cold and flu symptoms, Tianqi Dysmenorrhea capsule for menstrual pain, Deafness Tongqiao pills for ear-related issues, Wenweishu capsules for chronic gastritis, Zhitongtougu ointment for joint pain, and Chuzhang Zehaifu tablets for cataract. The company's prescription drugs cover areas such as cardiovascular health (Danshen granules and tablets), pediatric care (Taohuasan), and various other conditions including rhinitis, hyperthyroidism, and bacterial infections. Biostar also operates an online platform, the China Hepatitis Internet hospital, providing information and treatment options for HBV patients, as well as facilitating the purchase of HBV medicines. The company distributes its products through a network of distributors and sales personnel, reaching approximately 28 provinces across China.
What Products and Services Does BSPM Offer?
- Develops over-the-counter (OTC) pharmaceutical products.
- Manufactures prescription pharmaceutical products.
- Markets pharmaceutical products for various diseases and conditions.
- Offers Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B.
- Provides traditional Chinese medicines.
- Operates an online platform for HBV patients.
How Does BSPM Make Money?
- Develops and manufactures OTC and prescription pharmaceutical products.
- Sells products through distributors and a network of sales people in China.
- Operates an online platform (China Hepatitis Internet hospital) for HBV patients.
- Generates revenue from the sale of pharmaceutical products.
What Industry Does BSPM Operate In?
Biostar Pharmaceuticals operates within the Chinese pharmaceutical market, a large and rapidly growing sector driven by increasing healthcare expenditure and an aging population. The market is characterized by a mix of domestic and international players, with a growing demand for both OTC and prescription drugs. Biostar competes with other generic drug manufacturers, including BIOCQ, CLVR, CRFTF, CWWBF, and ELOX, as well as larger multinational pharmaceutical companies. The company's focus on traditional Chinese medicine and its established distribution network provide a competitive advantage in certain segments of the market.
Who Are BSPM's Key Customers?
- Patients in China seeking OTC medications for common ailments.
- Patients in China requiring prescription medications for various diseases.
- Hospitals and clinics in China that purchase pharmaceutical products.
- Distributors who sell Biostar's products to pharmacies and other retailers.
How Biostar Pharmaceuticals, Inc. Is Valued
Relative to its peer group, BSPM's quantitative score of 47/100 is roughly in line with the peer average of 56/100.
ROE -14%Key Financial Metrics
Return on equity for Biostar Pharmaceuticals, Inc. stands at -14.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.4%, showing how much profit it generates from its asset base. A current ratio of 1.31 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 4/9Financial Health
Biostar Pharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 0.02 places it in the distress zone, a signal of elevated financial risk.
BSPM Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Biostar's recent insider buying suggests that those with the deepest knowledge of the company see potential upside. This can be a strong signal, especially when coupled with positive developments in their core business areas.
- Community sentiment indicates growing optimism about Biostar's strategic partnerships and their potential to expand market reach. This positive outlook is crucial for attracting new investors.
- The company's focus on innovative pharmaceutical solutions is resonating well within the industry, positioning them as a potential disruptor in a niche market. This perception is building momentum.
- Positive chatter within the social trading community highlights the belief that Biostar is undervalued, with many seeing it as a long-term growth play.
Bear Case
- Recent market perception indicates concerns about Biostar's ability to scale production to meet growing demand. This operational challenge could hinder revenue growth.
- Bearish community views point to skepticism regarding the company's long-term financial stability, despite recent positive developments. This uncertainty can weigh on investor confidence.
- Insider activity, while showing some buying, also reveals instances of selling, raising questions about the overall conviction of company leadership. This mixed signal can create confusion.
- Market developments suggest that Biostar faces increasing competition from larger, more established players in the pharmaceutical sector. This competitive pressure could limit their market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BSPM Latest News
No recent news available for BSPM.
BSPM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BSPM.
Price Targets
Wall Street price target analysis for BSPM.
BSPM MoonshotScore
What does this score mean?
The MoonshotScore rates BSPM 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Ronghua Wang
CEO
Ronghua Wang serves as the CEO of Biostar Pharmaceuticals, Inc. He is responsible for managing the company's overall operations and strategic direction. His background includes experience in the pharmaceutical industry, with a focus on sales and marketing. He has been instrumental in expanding the company's distribution network and product portfolio. He oversees a workforce of approximately 200 employees.
Track Record: Under Ronghua Wang's leadership, Biostar Pharmaceuticals has focused on developing and marketing pharmaceutical products in China. Key milestones include the expansion of the company's OTC product line and the establishment of the China Hepatitis Internet hospital. However, the company's financial performance, as indicated by its negative profit margin, remains a challenge.
BSPM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Biostar Pharmaceuticals may not meet the listing requirements of higher tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. Companies in this tier often have limited financial disclosure and may not be subject to the same regulatory oversight as exchange-listed companies. This can result in increased risks for investors due to the potential for less transparency and greater information asymmetry. Investing in OTC Other stocks requires a higher degree of due diligence and risk tolerance.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Lack of regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Determine the company's ownership structure and potential conflicts of interest.
- Check for any history of fraud or regulatory violations.
- Consult with a financial advisor before investing.
- Established distribution network in China.
- Portfolio of both OTC and prescription drugs.
- Focus on traditional Chinese medicine.
- Online platform for HBV patients.
BSPM Healthcare Stock FAQ
What does the AI Score mean for BSPM?
BSPM holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Biostar Pharmaceuticals, Inc. focuses on developing, manufacturing, and marketing pharmaceutical products in China. Its portfolio includes both over-the-counter (OTC) and prescription medications …
What does Biostar Pharmaceuticals, Inc. do?
Biostar Pharmaceuticals, Inc. is a Chinese pharmaceutical company that develops, manufactures, and markets both over-the-counter (OTC) and prescription drugs. Its primary focus is on addressing common diseases and conditions in China, with a key product being Xin Ao Xing Oleanolic Acid capsule for chronic hepatitis B.
What are the main risks for BSPM?
The main risks for Biostar Pharmaceuticals, Inc. include its negative profit margin, limited financial resources, and dependence on a single key product. As an OTC-listed company, BSPM faces additional risks related to liquidity, disclosure, and regulatory oversight. Competition from larger pharmaceutical companies and regulatory changes in China also pose significant challenges. Investors should carefully consider these risks before investing in BSPM.
What are the key factors to evaluate for BSPM?
Biostar Pharmaceuticals, Inc. (BSPM) holds an AI score of 47/100 (low). Not financial advice.
How frequently does BSPM data refresh on this page?
BSPM's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BSPM's recent stock price performance?
Biostar Pharmaceuticals, Inc. (BSPM) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established distribution network in China. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BSPM overvalued or undervalued right now?
Biostar Pharmaceuticals, Inc. (BSPM) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BSPM before investing?
Before investing in Biostar Pharmaceuticals, Inc. (BSPM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding BSPM to a portfolio?
Key strength of Biostar Pharmaceuticals, Inc. (BSPM): Established distribution network in China. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be fully up-to-date.
- OTC stocks carry higher risks than exchange-listed stocks.